Shots:

• The approval is based on P-III IMpower130 study assessing Tecentriq + CT (carboplatin and nab-paclitaxel) vs CT alone in 723 CT naive patients in ratio (2:1) with stage IV non sq. NSCLC who do not have EGFR mutant or ALK-positive NSCLC
• The P-III IMpower130 study results: median OS (18.6 vs 13.9 mos.); mPFS (7.0 vs 5.5 mos.); ORR (49.2% vs 31.9%); mDoR (8.4 vs 6.1mos.); AEs (73.2% vs 60.3%)
• Tecentriq is a mAb targeting PD-L1 act by blocking its interaction with PD-1 and B7.1 receptors thus leading to the activation of T cells and is an approved therapy in multiple countries across the globe including the US and EU as a monothx. or combination therapy for NSCLC and SCLC

Click here to read full press release/ article 

Ref: Roche | Image: Roche